BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, September 28, 2023
Breaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeks
  • Brain with handshake and cityscape

    Acurastem, Takeda strike $580M licensing deal for ALS, neurodegenerative drugs

    Acurastem Inc. said on Sept. 25 that it struck an out-licensing deal potentially worth $580 million with Takeda Pharmaceutical Co. Ltd. to develop drugs for amyotrophic lateral sclerosis (ALS) and other PIKfyve gene-targeting therapeutics. Under the terms, Tokyo-headquartered Takeda obtains exclusive worldwide rights to Acurastem’s PIKfyve-targeting therapeutics, including Acurastem’s lead AS-202 asset, an antisense oligonucleotide therapy to treat ALS.
  • Japan’s MHLW approves slew of new drugs, including Eisai/Biogen’s Leqembi for Alzheimer’s

  • Peptidream, Genentech ink $1B deal for peptide-radioisotope drug conjugates

  • Chinabio 2023: Cansino, Gracell, Immuneonco’s C-suites offer IPO insights in China, US

  • Chinabio 2023: As tide turns to China, what will keep biotechs afloat in rocky capital, political seas?

  • Chinabio 2023: Big pharma scouts for innovation post-pandemic

  • News in brief

  • Acurastem, Takeda strike $580M licensing deal for ALS, neurodegenerative drugs

    Acurastem Inc. said on Sept. 25 that it struck an out-licensing deal potentially worth $580 million with Takeda Pharmaceutical Co. Ltd. to develop drugs for amyotrophic lateral sclerosis (ALS) and other PIKfyve gene-targeting therapeutics. Under the terms, Tokyo-headquartered Takeda obtains exclusive worldwide rights to Acurastem’s PIKfyve-targeting therapeutics, including Acurastem’s lead AS-202 asset, an antisense oligonucleotide therapy to treat ALS.
  • Japan’s MHLW approves slew of new drugs, including Eisai/Biogen’s Leqembi for Alzheimer’s

    Thanks to a raft of new approvals by Japan’s Ministry of Health, Labor and Welfare (MHLW), patients in Japan will soon have access to Biogen Inc./Eisai Co. Ltd.’s Leqembi (lecanemab), an amyloid-beta binder, for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease.
  • Peptidream, Genentech ink $1B deal for peptide-radioisotope drug conjugates

    Peptidream Inc. and Genentech Inc., a Roche Holding company, signed a deal worth up to $1 billion to discover and develop macrocyclic peptide-radioisotope (peptide-RI) drug conjugates. Peptidream, of Kawasaki, Japan, will use its peptide discovery platform system technology to discover, optimize and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech. Genentech will pay Peptidream an up-front payment of $40 million and up to $1 billion in potential development, regulatory, and commercial-based milestones. In addition, Peptidream is eligible to receive tiered royalties on net sales (ex-Japan) of any products arising from the collaboration.
  • Chinabio 2023: Cansino, Gracell, Immuneonco’s C-suites offer IPO insights in China, US

    Raising capital has always been a challenge for small to medium biotech firms worldwide, but the economic whiplash and the wider downturn across international markets post-pandemic have pushed Chinese biotechs to make-it-or-break-it scenarios for crossing the IPO threshold, speakers at the Chinabio Partnering Forum 2023 said in Shanghai.
  • Chinabio 2023: As tide turns to China, what will keep biotechs afloat in rocky capital, political seas?

    “Why do the top 10 pharmaceutical companies remain in the top 10?” asked Li Chen, founder and CEO of Hua Medicine, to audience members at the Chinabio Partnering Forum in Shanghai on Sept. 20. “[It comes down to] their ability to innovate themselves, but also the capability to acquire technology from partnerships, [to] manufacture and sell in countries like the U.S."
  • Chinabio 2023: Big pharma scouts for innovation post-pandemic

    Despite China’s near-frozen startup scene and increasingly cautious foreign investors following the COVID-19 pandemic, multinational pharmaceutical firms continued to scout for innovative up-and-coming Chinese biotechs in Shanghai at Chinabio Partnering Forum 2023 over its two-day run.
  • News in brief

    BioWorld Asia briefs for September 26,
  • Wuhan YZY raises $15 million in Hong Kong IPO to advance BsAbs

    Wuhan YZY Biopharma Co. Ltd. made its debut on the Hong Kong Stock Exchange, raising HK$121 million (US$15.48 million) in its IPO on Sept. 22, with shares (HKEX:02496) opening at the lower end of its range at HK$16 per share and ending the day at HK$16.60, a rise of 3.75%.
  • Inventiva licenses NASH candidate for Japan, South Korea development

    Inventiva SA is getting $10 million up front and the possibility of $231 in clinical, regulatory and commercial milestones by exclusively licensing its nonalcoholic steatohepatitis (NASH) candidate, lanifibranor, to Hepalys Pharma Inc. to sell in Japan and South Korea, two massive markets for the indication.
  • Everest licenses Asian rights to Kezar’s autoimmune drug zetomipzomib

    Everest Medicines Ltd. is in-licensing Kezar Life Sciences Inc.’s phase II autoimmune disease candidate, zetomipzomib in a deal worth $132 million for greater China, South Korea and southeast Asia rights. Kezar’s lead molecule zetomipzomib (KZR-616) is a first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
  • Abbvie drops full CD47 collaboration, as I-Mab pushes ahead with phase III

    I-Mab Biopharma Co. Ltd. has regained full rights to its CD47 antibody program from Abbvie Inc., including lemzoparlimab, the most advanced candidate. The move, disclosed in a Sept. 22 U.S. SEC filing, eliminates the potential $1.295 billion in milestones associated with the amended collaboration deal signed in 2022.

BioWorld Insider Podcast

Google’s Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring to drug development in the relatively near future.

Listen now

Analysis and data insight

  • Nonprofit stamp

    Biopharmas receive $1.43B in BARDA grants in 2023

    Grant
    Biopharma grants are up nearly 150% compared to the same time period last year, largely due to a number of $100 million-plus grants from the Biomedical Advanced Research and Development Authority (BARDA). Meanwhile, nonprofit deal value has declined year-over-year, with the number of transactions...
  • Syringe and capsules atop lab chart

    Clinical trial data down from 2021 but up 18% from 2019

    Clinical
    The first seven months of 2023 saw clinical trial data up 1.43% compared to the same time period last year. From January through July this year, BioWorld reported on 2,064 drugs in phase I-III, compared to 2,035 in the same time period in 2022. The number of trial updates is down 14.07% from the...
  • Concept of business partnership

    First seven months of 2023 sees $105.4B in biopharma deals and $37.6B in M&As

    Deals and M&A
    The June dip in biopharma deal value was short-lived, with July seeing 106 deals worth $17.57 billion, up 72.03% from $10.22 billion in July 2022.
  • Merck leads in 1H23 clinical trial updates; percentage of COVID-19 therapies continues decline

    Clinical
    Clinical data in the first half of 2023 is up 1.51% compared to the same time period last year. So far in 2023 BioWorld reported on 1,810 drugs in phase I-III, compared to 1,783 in the first half of 2022. The number of trial updates is down 13.6% from the 2,095 in 2021, but more than 2020’s 1,799...
More in Analysis and data insight

Today's news in brief

  • Appointments and advancements for Sept. 26, 2023

  • Conference data for Sept. 19, 2023: IASLC-WCLC

  • Financings for Sept. 26, 2023

  • In the clinic for Sept. 26, 2023

  • Other news to note for Sept. 26, 2023

  • Regulatory actions for Sept. 26, 2023

Deals and M&A

  • Otsuka to acquire Mindset for $50M in move to bolster psychiatric pipeline

  • Verismo, U Penn team up on two CD19 binders for novel CAR T

  • SK Bioscience, Vaxxas partner to develop needle-free typhoid vaccine

  • Verastem, Genfleet to develop compounds targeting RAS pathways in deal worth up to $625M

  • Imugene in-licenses Precision Bioscience’s allogeneic CD19 CAR T in $227M deal

  • Celltrion, Celltrion Healthcare merger kicks off, rolling three-into-one ‘big pharma’

  • Hengrui inks $1B out-licensing deal for asthma drug with One Bio

  • Astellas returns two gene therapies to Modalis

  • Settling debt, strengthening ties: Novavax hands 6.45% stake to SK Bioscience

  • Amarin taps Lotus to expand Vazkepa in SE Asia, Korea

Financings

  • IPO stock market ticker

    Following Hong Kong IPO, Immuneonco looks to be rising star

    Cancer
    After raising HKD$320 million (US$40.8 million) in its IPO on the Hong Kong Stock Exchange last week, Immuneonco Biopharmaceuticals Co. Ltd.’s stock has continued to rise, and analysts are expecting the Hong Kong market to pick up after a slack start to the year.
  • Opthea to raise AU$80M to continue phase III wet AMD trials for lead candidate OPT-302

    Ocular
  • Boryung invests $60M in Axiom for R&D station in space

    Series C
  • NDA submitted, Jyong seeks up to $40M in IPO for urinary disorders

    Genitourinary/Sexual Function
  • Biologic cancer drug developer Sunho targets HK IPO

    Cancer
More in Financings
black cortellis ad

Australia

  • Dendrimer illustration

    Starpharma’s dendrimer platform delivers impressive results in bowel, ovarian cancer

    Clinical
    Starpharma Holdings Ltd.'s nanoscale drug delivery technology shows enhanced safety and durable responses in phase II trials compared to standard of care therapies in patients with advanced colorectal and ovarian cancer.
  • Imagion explores global partnerships to expand molecular MRI footprint for early cancer detection

    Cancer
    Imagion Biosystems Ltd. signed a flurry of deals recently to expand its pioneering molecular magnetic resonance imaging platform Magsense beyond Australia and into additional indications to detect cancer earlier.
  • Incannex to begin pivotal trials in US for synthetic cannabinoid for sleep apnea

    Clinical
    Incannex Healthcare Ltd. is gearing up to begin a pivotal phase II/III trial in the U.S. for its lead asset, IHL-42X (dronabinol/acetazolamide), a synthetic cannabinoid combination drug for sleep apnea.
  • Adalta gears up for phase II IPF trials for its i-body derived from shark antibodies

    Clinical
  • IAS 2023: Sydney close to eradicating HIV but experts warn the last mile is the hardest

    Conferences
  • Neuren, Acadia expand Daybue partnership; global deal worth $527M+

    Deals and M&A
  • Haemalogix’s Kappamab hits endpoints in phase IIb myeloma trial

    Clinical
More in Australia

China

  • Bloodstream with red and white blood cells and platelets

    Hutchmed’s sovleplenib meets primary, secondary endpoints in China phase III ITP trial

    Clinical
    Hutchmed (China) Ltd.’s sovleplenib (HMPL-523) met the primary endpoint of durable response rate and all secondary endpoints in the pivotal phase III trial in adults with primary immune thrombocytopenia (ITP) in China.
  • Innovent scores first approval for PCSK9 inhibitor in China

    Regulatory
    China’s National Medical Products Administration has approved Innovent Biologics Inc.’s proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor, Sintbilo (tafolecimab), making it the first first locally developed PCSK9 monoclonal antibody to be approved in China.
  • Multiple myeloma illustration

    Oricell clears IND hurdle for homegrown CAR T in China

    Regulatory
    Oricell Therapeutics Co. Ltd. has become the latest Chinese biotech to advance an independently developed CAR T therapy, announcing Aug. 10 that China’s regulatory body gave IND approval for Oricar-017. Oricar-017 is the Shanghai-based biotech’s GPRC5D-directed CAR T therapy developed to treat...
  • Ivy Wang, co-founder and executive vice president, Biocity Biopharmaceutics

    China’s Biocity expands to US with pipeline of bispecific antibodies and ADCs

    Newco news
    Biocity Biopharmaceutics Co. Ltd. is advancing its pipeline of differentiated, modality-independent therapeutics for oncology that include small molecules, monoclonal and bispecific antibodies, as well as antibody-drug conjugates (ADCs). The Wuxi, China-headquartered company is focused on...
  • Dividing breast cancer cell.

    Kelun’s Trop2 ADC meets primary endpoints in phase III triple-negative breast cancer trial

    Clinical
    Kelun-Biotech Biopharmaceutical Co. Ltd.’s trophoblast cell-surface antigen 2 (Trop2)-targeted antibody-drug conjugate (ADC), SKB-264, met the primary endpoint of progression-free survival (PFS) in a phase III trial in patients with unresectable locally advanced, recurrent or metastatic...
More in China

Clinical

  • KIW 2023: ‘HLB ready to take 50% of liver cancer market with rivoceranib’

  • Genexine drug meets phase III endpoint in pediatric growth hormone deficiency

  • Omnix lining up phase II trial of insect-derived antibiotic

  • Tarsier’s eye drop for uveitis misses phase III endpoint; silver lining?

  • LG Chem, JW Pharma go toe-to-toe in Asia gout drug race

  • Kickoffs for China drug trials: Leads, Hanchorbio, Transcenta, Everest

  • Connext to kick off phase I/II trial for ‘high-quality, affordable’ Dupuytren’s contracture drug

  • Hanmi repositions once-returned GLP-1 drug to obesity

  • Sumitomo/Otsuka’s ulotaront misses phase III endpoints in schizophrenia

  • Cellid gains MFDS nod for omicron COVID-19 vaccine trial; new cases, vaccine waste surges

Regulatory

  • Rx quality problems continue to aggravate supply issues

    U.S.
    In a balancing act between supply and drug quality, the U.S. FDA tipped the scales on behalf of quality, slapping an import alert on Intas Pharmaceuticals Ltd. in June, followed by a July 28 warning letter requiring the India-based company to develop and implement a global corrective action and...
  • China’s NMPA accepts Luye’s NDA for long-acting rotigotine to treat Parkinson's disease

    Neurology/Psychiatric
  • Mesoblast’s hopes dashed again with second FDA complete response letter for remestemcel-L

    Immune
  • Kissei withdraws NDA for rovatirelin for spinocerebellar degeneration in Japan

    Neurology/Psychiatric
  • Korea’s FTC slams GSK, domestic vaccine makers with $32M for price-fixing

    Vaccine
More in Regulatory
black cortellis ad

Newco news

  • Dotbio CEO Ignacio Asial with team

    Dotbio emerges with $5.6M pre-series A to advance multifunctional antibodies

    Cancer
    Emerging from stealth mode, new immuno-oncology company Dotbio Pte. Ltd. closed an oversubscribed $5.6 million pre-series A round to accelerate development of its multifunctional and intracellular antibody therapies.
  • Viage to advance gut-drug for cognitive impairment to phase II

    Neurology/Psychiatric
    Viage Therapeutics Inc. – formerly Digestome Therapeutics Inc. – on July 26 unveiled positive data from its phase I study on DGX-001 for mild cognitive impairment in Alzheimer’s disease (AD) and Parkinson’s (PD). The randomized, double-blind, placebo-controlled study demonstrated changes in brain...
  • Argenica raises AU$4M to advance neuroprotective agent in ischemic stroke

    Asia-Pacific
    After raising AU$4 million (US$2.6 million), Argenica Therapeutics Pty. Ltd. is gearing up to begin phase II trials in ischemic stroke for ARG-007, a glutamate receptor modulator that is believed to reduce brain tissue death after stroke.
  • Itabmed gets nod to start clinical trial for CD3-activating bispecific antibody in China

    Asia-Pacific
  • Incannex is changing treatment paradigms with pipeline of psychedelics and cannabinoids

    Regulatory
  • Albatroz launches with $3M in seed funding to tackle new target for solid tumors and arthritis

    Cancer
  • Cargene’s siRNA therapy has potential to regenerate the liver and reverse fibrosis

    Gastrointestinal
More in Newco news

Science

  • Pan-cancer studies take pan-oramic view on proteogenomics

    Omics
    The vast variety of tumors makes each cancer a world. For researchers, understanding the commonalities and divergences in their molecular underpinnings could help find successful treatments. Scientists from the Clinical Proteomic Tumor Analysis...
  • In Zoonomia project, evolutionary lens hones search for functional genomic variants

    Genetic/Congenital
    A base-by-base comparison of the genome sequences of 240 species of mammals has pinpointed sites in the human genome where mutations are likely to cause disease. The sites are all perfectly conserved across the mammalian family tree over 100...
  • Biocom 2023: There’s science going on 250 miles above your head

    Analysis and data insight
    Performing experiments and potentially manufacturing products in space offers some unique advantages in a near-zero gravity environment. Space changes buoyancy, hydrostatic pressure and convective heat flow. Researchers are studying how those...
  • Nanomaterial allows location-specific fat targeting

    Clinical
    The positively charged nanoparticle polyamidoamine generation 3 (P-G3) can be specifically targeted to either visceral or subcutaneous fat, and affects both types of fat in different ways, researchers from Columbia University reported in two...
  • Amyloid plaques recast as cause of neural network dysfunction

    Neurology/Psychiatric
    Researchers have identified a link between amyloid plaques and dysfunctional neuronal conduction in animal models of Alzheimer’s disease (AD). Their study, which was published in the Dec. 1, 2022, issue of Nature, suggests new ways to think about...
  • Innate immunity can drive radiation-induced abscopal effect

    Clinical
    A combination of radiation therapy and CD47 blockade induced an abscopal effect in animal studies even in animals that lacked T cells, researchers reported in the Nov. 21, 2022, online issue of Nature Cancer.
More in Science

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • AI: driving drug development from effective to remarkable
  • The struggle is real: The first half of 2023 was an uphill climb
  • The biosimilars challenge to Humira revs up
  • Preventing opioid overdoses with a smart patch
  • Better times ahead for the biopharma sector? Could be, the new numbers say
  • Radiopharmaceuticals: The next big disrupter?
  • Cambrian carves out a new niche as it works to keep people from getting sick
  • Rethinking obesity: Fitness may be more directly linked to health than weight
  • Looking ahead to 2023: CEOs contemplate the new normal
  • $1B+ biopharma deals keep values afloat, even amid muted volume

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing